Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological MalignanciesAaron Cumpston, Abraham S. Kanate, Ryan Caddell et al.|Antimicrobial Agents and Chemotherapy|2015Cited by 68
Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet FormulationMorgan Belling, Aaron Cumpston, Nilay Shah et al.|Leukemia Research and Treatment|2017Cited by 27
Triheptanoin for the treatment of long‐chain fatty acid oxidation disorders: Final results of an open‐label, long‐term extension studyJerry Vockley, Antonio Nino Ramirez, Elaine Murphy et al.|Journal of Inherited Metabolic Disease|2023Cited by 21
IMPROVEMENTS IN MAJOR CLINICAL EVENTS IN CHILDREN TREATED WITH TRIHEPTANOIN FOR LONG-CHAIN FATTY ACID OXIDATION DISORDERS (LC-FAOD)Kathryn Ray, Jerry Vockley, Laura Rosa Pisani et al.|Molecular Genetics and Metabolism|2022Cited by 0